Personalis Other Non-Current Liabilities 2018-2024 | PSNL

Personalis other non-current liabilities from 2018 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Personalis Annual Other Non-Current Liabilities
(Millions of US $)
2023 $10
2022 $0
2021 $2
2020 $1
2019 $
2018 $0
2017 $
Personalis Quarterly Other Non-Current Liabilities
(Millions of US $)
2024-06-30 $3
2024-03-31 $6
2023-12-31 $10
2023-09-30 $4
2023-06-30 $4
2023-03-31 $4
2022-12-31 $0
2022-09-30 $0
2022-06-30 $0
2022-03-31 $2
2021-12-31 $2
2021-09-30 $2
2021-06-30 $2
2021-03-31 $0
2020-12-31 $1
2020-09-30 $0
2020-06-30 $0
2020-03-31 $1
2019-12-31
2019-09-30 $1
2019-06-30 $0
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.315B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.120B 6.83
Dr Reddy's Laboratories (RDY) India $13.079B 19.59
BridgeBio Pharma (BBIO) United States $5.045B 0.00
Bausch Health Cos (BHC) Canada $2.956B 2.23
Amphastar Pharmaceuticals (AMPH) United States $2.438B 13.65
Supernus Pharmaceuticals (SUPN) United States $1.771B 357.00
Taysha Gene Therapies (TSHA) United States $0.449B 73.00
Assembly Biosciences (ASMB) United States $0.117B 0.00
Acasti Pharma (ACST) Canada $0.028B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00